SCHEMBL5651722

SCHEMBL5651722

COc1cc(N)c(OC)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.53
ALDH1A1 P00352 3/20 0.52
CYP3A4 P08684 2/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.52
THRB P10828 1/20 0.52
KMT2A Q03164 1/20 0.52
TUBB4A P04350 2/20 0.49
TUBB P07437 2/20 0.49
TUBA3C P0DPH7 2/20 0.49
TUBA1B P68363 2/20 0.49
TUBA4A P68366 2/20 0.49
TUBB4B P68371 2/20 0.49
TUBB3 Q13509 2/20 0.49
TUBB2A Q13885 2/20 0.49
TUBB8 Q3ZCM7 2/20 0.49
TUBA3E Q6PEY2 2/20 0.49
TUBA1A Q71U36 2/20 0.49
TUBA1C Q9BQE3 2/20 0.49
TUBB6 Q9BUF5 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15933604 0.85 ALDH1A1 (0.53) CYP1A2ALDH1A1CYP3A4MAPTMEN1
SCHEMBL686849 0.83 CYP1A2 (0.64) CYP1A2ALDH1A1CYP3A4MAPTTUBB4A
SCHEMBL8708885 0.81 CYP1A2 (0.45) CYP1A2ALDH1A1CYP3A4MAPTMEN1
SCHEMBL29113733 0.79 ALDH1A1 (0.45) CYP1A2ALDH1A1CYP3A4MAPTMEN1
SCHEMBL2841590 0.79 ALDH1A1 (0.54) CYP1A2ALDH1A1CYP3A4MAPTMEN1
SCHEMBL2529901 0.79 ACHE (0.46) ALDH1A1CYP3A4MAPTTUBB4ATUBB
SCHEMBL11848358 0.77 ALDH1A1 (0.43) CYP1A2ALDH1A1CYP3A4MAPTMEN1
Hydrochloric Acid SCHEMBL8521226 0.77 MAPT (0.46) ALDH1A1CYP3A4MAPTMEN1THRB
SCHEMBL5035434 0.77 CA2 (0.46) CYP1A2ALDH1A1CYP3A4MAPTMEN1
SCHEMBL9349720 0.77 ALDH1A1 (0.52) CYP1A2ALDH1A1CYP3A4MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992016509-A1 MULTISUBSTITUTED 1-HYDROXY-9-ACRIDONES WITH ANTICANCER ACTIVITY SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-10-01 WO claimed
CN-119764062-A Solid electrolytic capacitor and method for manufacturing the same 日本贵弥功株式会社 2025-04-04 CN disclosed
CN-114868217-B Hybrid electrolytic capacitor and method for manufacturing same 日本贵弥功株式会社 2025-02-25 CN disclosed
EP-4080531-B1 SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR MANUFACTURING SAME NIPPON CHEMICON (JP) 2024-09-18 EP disclosed
US-12009158-B2 Solid electrolytic capacitor and method for manufacturing same NIPPON CHEMI-CON CORPORATION (JP) 2024-06-11 US disclosed
US-11929214-B2 Hybrid electrolytic capacitor and method for manufacturing same NIPPON CHEMI-CON CORPORATION (JP) 2024-03-12 US disclosed
US-20230029692-A1 SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR MANUFACTURING SAME NIPPON CHEMI-CON CORPORATION (JP) 2023-02-02 US disclosed
US-20230017930-A1 HYBRID ELECTROLYTIC CAPACITOR AND METHOD FOR MANUFACTURING SAME NIPPON CHEMI-CON CORPORATION (JP) 2023-01-19 US disclosed
EP-4080531-A1 SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR MANUFACTURING SAME Nippon Chemi-Con Corporation (JP) 2022-10-26 EP disclosed
CN-114868217-A Hybrid electrolytic capacitor and method for manufacturing the same 日本贵弥功株式会社 2022-08-05 CN disclosed
US-20140016248-A1 POLYMERIZATION SOLUTION, CONDUCTIVE POLYMER FILM OBTAINED FROM THE POLYMERIZATION SOLUTION, AND SOLID ELECTROLYTIC CAPACITOR NIPPON CHEMI-CON CORPORATION (JP) 2014-01-16 US disclosed
CN-103430262-A Polymerization liquid, conductive polymer film obtained from the polymerization liquid, and solid electrolytic capacitor NIPPON CHEMICON 2013-12-04 CN disclosed
CN-101786980-B Synthesis method of isatin derivatives BINGHAI KANGJIE CHEMICALS CO LTD 2012-12-05 CN disclosed
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors WYETH (US) 2007-12-27 US disclosed
WO-2005115145-A2 QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS WYETH (US) 2005-12-08 WO disclosed
US-5296602-A Condensing substituted ortho-halo- or ortho-aminobenzoic acid with meta-halo- or meta-aminoanisole, cyclizing, N-alkylating, de-O-methylating SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1994-03-22 US disclosed
WO-1992016509-A1 MULTISUBSTITUTED 1-HYDROXY-9-ACRIDONES WITH ANTICANCER ACTIVITY SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-10-01 WO disclosed
EP-0214310-B1 CONDUCTIVE POLYMER SOLUTION AND PROCESS FOR PRODUCING CONDUCTIVE ARTICLES FROM THE SOLUTION SHOWA DENKO KABUSHIKI KAISHA (JP) 1990-09-19 EP disclosed
US-4762644-A AROMATIC POLYAMINE WITH ANIONICDOPES SHOWA DENKO KABUSHIKI KAISHA (JP) 1988-08-09 US disclosed
EP-0214310-A1 CONDUCTIVE POLYMER SOLUTION AND PROCESS FOR PRODUCING CONDUCTIVE ARTICLES FROM THE SOLUTION SHOWA DENKO KABUSHIKI KAISHA (JP) 1987-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors KDR, FLT1, FLT4 CYP1A2 804/4885ALDH1A1 530/4885CYP3A4 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.